Inhibrx, Inc. (INBX)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 34.09 |
| Open | 34.03 |
| Bid | 34.00 x 200 |
| Ask | 34.07 x 200 |
| Day's range | 33.72 - 34.14 |
| 52-week range | 14.31 - 39.79 |
| Volume | |
| Avg. volume | 477,452 |
| Market cap | 1.614B |
| Beta (5Y monthly) | 2.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.12 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 35.50 |
ZacksInhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -61.68% and 1,534%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
PR NewswireInhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with three clinical programs in development and a strong emerging pipeline, today reported financial results for the fourth quarter and fiscal year 2023.
ZacksPharma Stock Roundup: JNJ Reports Q4 Earnings, SNY Inks M&A Deal With INBX
J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sanofi (SNY) is set to acquire Inhibrx's (INBX) rare disease pipeline candidate, INBRX-101.
© 2024 Yahoo. All rights reserved.